Home Sleep Tests for Obstructive Sleep Apnea (OSA)

Mukesh Kapoor, MD, and Glen Greenough, MD

Obstructive sleep apnea (OSA) is a fairly common condition that, if left untreated, can lead to complications such as high blood pressure and heart disease. Polysomnography (PSG) is the most accurate method for diagnosing OSA, but it is a cumbersome and expensive test. A well-validated, easier to perform and less expensive alternative is the home sleep test (HST). The purpose of this review is to educate the primary care provider about the important differences between PSG and HSTs, the advantages and limitations of both modalities, identifying patients who are appropriate candidates for the HST, identifying patients in whom the HST should not be performed, and further evaluation of patients who have a negative HST. (J Am Board Fam Med 2015;28:504–509.)

Keywords: Home Sleep Testing, Monitoring, Obstructive Sleep Apnea, Out of Center Sleep Testing, Portable Monitoring

Obstructive sleep apnea (OSA) is thought to affect between 3% and 7% of the population, although a significantly higher prevalence is seen in certain subgroups of patients, such as those with atrial fibrillation, congestive heart failure, resistant hypertension, type 1 diabetes mellitus, type 2 diabetes mellitus, and morbid obesity. One study showed that approximately 32% of patients in a primary care setting have a high pretest probability for OSA. Some symptoms associated with OSA include snoring, observed pauses in breathing during sleep, frequent awakenings, nocturia, nonrefreshing sleep, and feeling tired and sleepy during the day. Untreated OSA can increase the risk for developing other medical problems, including high blood pressure and heart disease.

The most accurate method for diagnosing OSA is by polysomnography (PSG), which requires that the patient sleep overnight in a sleep laboratory. Multiple sensors are used during PSG, including electroencephalography (EEG) leads, which record brain activity; electrooculography leads, which measure eye movement; electromyography leads, which measure muscle tone; a nasal pressure transducer and oronasal thermistor, which measures respiratory airflow; respiratory inductance plethysmography belts, which measure respiratory effort; electrocardiography leads, which measure cardiac activity; a pulse oximeter probe, which measures oxygen saturation; and limb leads, which measure limb movements. EEG allows for the detection of different sleep stages, analysis of sleep architecture, differentiation between awake and sleep, and identification of abnormal brain activity such as seizures. Electrooculography and electromyography help in the detection of rapid eye movement (REM) sleep, as there are characteristic eye movements and loss of muscle tone during this sleep stage. Trained sleep technologists set up the patient for PSG in the sleep laboratory and use a video camera to monitor the patient during this test. The position of the patient (supine vs. side vs. prone) and abnormal body movements can be visually recorded. Some patients can have positional sleep apnea, which is more severe in the supine position and less so when positioned on the side. If a patient is spending the majority of the night on their side, the technologist can intervene and have them spend some time on their back to look for such
a positional change. If there is evidence of significant OSA during the early part of this test, the technologist can initiate continuous positive airway pressure titration and continue this for the remainder of the study time.

Some patients undergoing PSG may experience anxiety and discomfort associated with sleeping outside of the home environment. Depending on the geographic location, PSG might be unavailable or there might be a long wait time before a patient can undergo this test. PSG is cumbersome because multiple sensors (detailed above) are used, and it can be uncomfortable for some patients. PSG is also expensive; reimbursement from the Centers for Medicare & Medicaid Services (CMS) is approximately $700.

A well-validated alternative to PSG is the home sleep test (HST). This is also referred to as a portable monitor or an out-of-center sleep test. As the name of this test suggests, the patient stays in their home when it is performed. This is especially beneficial for patients who might feel anxious staying overnight in a sleep laboratory for PSG. The HST has fewer sensors, is more compact, and is less cumbersome to perform. A technologist is not needed to monitor the patient during the HST. Given the prevalence of OSA, as discussed earlier, the HST can be a useful tool for primary care providers to evaluate their patients suspected to have this disorder. The HST can aid in the early diagnosis and initiation of treatment in these patients. The HST is also less expensive; reimbursement from the CMS is approximately $250.

The HSTs most commonly used in routine clinical practice have sensors that measure only respiratory airflow, respiratory effort, and oxygen saturation. Some HSTs have a built-in sensor to detect body position and an actigraph, which can be used as a surrogate marker for identifying when the patient is awake and sleep. The majority of commonly used HSTs do not include EEG monitoring. The few HSTs that do have the capability of EEG monitoring are not widely available and are more cumbersome and expensive.

Patients with OSA can have several different kinds of respiratory abnormalities. They can have apneas, which are defined as the cessation of breathing for ≥10 seconds. Another type of respiratory abnormality is the hypopnea, which represents attenuation in the depth of respiration for at least 10 seconds that leads to desaturation or arousal from sleep. Patients may also have other respiratory abnormalities during which there is increased effort to breathe, leading to an arousal. These episodes are called respiratory effort–related arousals. The above respiratory abnormalities have very specific technical definitions, and the reader is referred to the American Academy of Sleep Medicine (AASM) guidelines on scoring respiratory events for further details.

The principal way to detect arousals from sleep is through the use of EEG. It is important for health care providers to recognize that the most commonly used HSTs do not typically include EEG and thus cannot detect respiratory events that lead only to an arousal. Thus a patient with OSA consisting of predominantly arousal-based respiratory events can have a negative HST. This is especially important in pediatric patients and patients who have a low body mass index (BMI) because both are more likely to have respiratory events that lead to an arousal rather than desaturation.

The parameters which are commonly measured by a HST are also recorded during PSG in addition to several other variables including brain activity through EEG. Thus, having EEG during PSG allows for the detection of respiratory events that are associated with arousals. The EEG component of PSG also allows one to know when a patient is awake and when they are asleep, providing a more accurate assessment for the presence of OSA and its severity. For example, a patient undergoing PSG may spend 10 hours in bed on the night of the test, but the EEG may show that the patient actually slept for only 5 hours. If a total of 100 respiratory events were recorded during the test, one would calculate the severity of this patient’s sleep apnea at 100 events in 5 hours, or 20 events/h. By contrast, a HST cannot differentiate between wake and sleep. If the above patient were to undergo a HST, the severity of their sleep apnea would be calculated at 100 events (in all likelihood the HST would detect fewer of the respiratory events as well, but for argument’s sake we will leave the number at 100) in the total recording time of 10 hours, or 10 events/h. Thus a HST tends to underestimate the severity of sleep apnea. This is especially of consequence in patients with mild sleep apnea in whom the HST can be negative because of the above. While some HSTs use actigraphy to differentiate between wake and sleep, one must remember that this is only a surrogate marker and can give flawed
results, particularly in the presence of periodic limb movements, body movements following an arousal, and in patients with REM sleep behavior disorder.\(^\text{11}\)

The AASM recommends that the HST should be used only in patients with a high pretest probability for moderate to severe OSA.\(^\text{26}\) Unfortunately, in our current health care environment, the majority of patients suspected of having OSA are channeled toward getting the HST, irrespective of their pretest probability.\(^\text{27}\) This increases the risk of having false-negative results with the HST. Many patients and clinicians are falsely reassured by a nondiagnostic HST. Not acting on these negative results by pursuing PSG can leave a patient with OSA undiagnosed.

A study published by a referral sleep disorders center looked at 187 patients who were suspected of having OSA (history of snoring along with an Epworth score >7 and/or a history of tiredness) but had a negative HST.\(^\text{28}\) All these patients underwent PSG, which showed that 90% of them had OSA (26% had mild OSA, 43% had moderate OSA, and 21% had severe OSA). The fact that such a significant number of patients with a negative HST were found to be positive for OSA on PSG was likely secondary to several factors, including the inability of the HST device to detect respiratory events which were only associated with arousals, the use of total recording time in lieu of total sleep time, and the use of the HST device in a population of patients who might not have had a high pretest probability for moderate to severe OSA.

The AASM recommends that the HST should not be used in patients with significant comorbid medical conditions (such as those with moderate to severe pulmonary disease, neuromuscular disease, and congestive heart failure) that may degrade the accuracy of this test and in patients suspected of having other sleep disorders (such as central sleep apnea, periodic limb movement disorder, insomnia, parasomnias, circadian rhythm disorders, narcolepsy, and REM sleep behavior disorder).\(^\text{26}\) The AASM also recommends against using the HST for screening asymptomatic populations.\(^\text{26}\)

There are no clear-cut guidelines for sleep testing in obese (BMI $\geq 30$ kg/m\(^2\)) patients suspected of having OSA. Obesity by itself is not an indication for obtaining a PSG. Obese patients who are suspected of having obesity hypoventilation syndrome (OHS), however, should undergo PSG. The incidence of OHS increases with an increase in BMI.\(^\text{29–31}\) It is therefore advisable to perform PSG in patients with morbid obesity (BMI $\geq 40$ kg/m\(^2\)).

Primary care physicians frequently have patients with hypertension and diabetes mellitus. Neither of these conditions is a contraindication to performing the HST.

As mentioned earlier, the most commonly used HSTs lack EEG monitoring and thus should not be used in patient suspected of having nocturnal seizures. Other patients who are poor candidates for the HST include those in whom hypoventilation (such as patients using narcotics, those who have neuromuscular disease, or those who have a high BMI and could have OHS) or nocturnal arrhythmias are suspected.\(^\text{32}\) Patients who have low oxygen saturation at baseline or are receiving supplemental oxygen are also poor candidates for the HST.\(^\text{32}\) In addition, the HST should not be used in pediatric patients because it can miss arousal-based hypopneas, which tend to be more frequent in this population.\(^\text{24}\)

If the patient spends the majority of the night on their side or outside of REM sleep, one might never know the true severity of their OSA because the latter tends to be worse in the supine position and during REM sleep.\(^\text{12}\) Some HSTs have a body position monitor whereas others do not. The most commonly available HSTs do not have EEG monitoring and therefore cannot record sleep stages. Body position and sleep stages are routinely recorded during PSG. This can quantify the exact duration of time spent by the patient in the supine position and in REM sleep. Other problems with the HST include a data loss rate of between 3% and 18%.\(^\text{13}\) As opposed to PSG, loss of a sensor signal cannot be corrected during a HST because of the lack of live monitoring and the absence of a technologist during this test. For similar reasons, continuous positive airway pressure titration cannot be performed during a HST.\(^\text{13}\)

There is a unique HST that collects peripheral arterial tone (PAT), oxygen saturation, heart rate, and actigraphy data.\(^\text{32}\) This device is validated for the diagnosis of OSA.\(^\text{22,33–36}\) The PAT signal is a measure of sympathetic activity and is augmented, along with an increase in the heart rate and a decrease in oxygen saturation, at the termination of a respiratory event.\(^\text{32,34}\) Using the above measurements, this device can indirectly detect respiratory events. It also has an built-in algorithm that uses the PAT and actigraphy data to estimate sleep stages.\(^\text{32}\) This device does not, however, measure direct respiratory flow and respira-
tory effort and thus cannot distinguish between cen-
tral apneas, obstructive apneas, and hypopneas.34 In
addition, this device has no way of quantifying the
cause of increased sympathetic activity which can also
occur in patients who have periodic limb move-
ments.34 Lastly, the detection of sleep stages by this
device has only moderate agreement with the more
standard technique of PSG.37

Figure 1. A suggested algorithm for using home sleep testing (HST) in adult patients suspected of having
obstructive sleep apnea (OSA). Note that HST should not be used in pediatric patients. *Significant comorbid
medical disorders include conditions such as moderate to severe pulmonary disease, neuromuscular disease,
and congestive heart failure which may degrade the accuracy of the home sleep test. Patients who have low baseline
oxygen saturation or are on supplemental oxygen are also poor candidates for a home sleep test. Note that
hypertension and diabetes mellitus are not contraindications for obtaining a home sleep test. See manuscript text
for discussion on decision making in obese patients. †Comorbid sleep disorders include conditions such as
central sleep apnea, periodic limb movement disorder, insomnia, parasomnias, circadian rhythm disorders,
narcolepsy, and REM sleep behavior disorder. Central sleep apnea is often seen in patients with heart failure and
those on narcotic medications. ‡Causes of hypoventilation include neuromuscular disease, restrictive lung
disease, and use of narcotic medications. Patients with an elevated body mass index are also at risk for
hypoventilation. PSG, polysomnography. (Adapted with permission from Collop et al.26)
When faced with a patient suspected of having OSA, a primary care provider may choose either to refer their patient to a board-certified sleep specialist for further evaluation or to directly order a HST. When electing to do the latter, the primary care provider should be aware of the type of device being used, along with its sensitivity and specificity in different populations. The presence of prolonged sustained hypoxemia, central apneas, mixed apneas, or a negative HST are indications for referring a patient for PSG. Other things to keep in mind are that at least 300 minutes of recording time are needed during a HST for accurate diagnosis of OSA and its severity, and that manual scoring is superior to automatic scoring.39–42A suggested algorithm for using the HST is shown in Figure 1.

The HST is an important tool if used and interpreted in the right manner in the right population. A patient’s symptoms and examination must be kept in mind when determining the appropriateness for ordering a HST, which has the potential to save money, is easy to perform, improves access to sleep testing, and can be done in the patient’s home. It must be remembered, however, that a patient suspected of having OSA and a negative HST should undergo PSG for further diagnostic evaluation.26,28

References


